The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK),
and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with
either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07349537.
Locations matching your search criteria
United States
Florida
Tampa
Moffitt Cancer CenterStatus: Active
Name Not Available
This is an open-label, multicenter, Phase 1/1b study of RMC-5127 in adults with advanced
KRAS G12V-mutant solid tumors to evaluate the safety, tolerability, pharmacokinetics
(PK), and preliminary clinical activity. The study consists of three arms: RMC-5127
monotherapy arm, RMC-5127 plus daraxonrasib combination arm, and RMC-5127 plus cetuximab
combination arm. All arms consist of two parts: Part 1- dose exploration and Part 2- dose
expansion. Both parts of the monotherapy arm may include Food Effect Cohorts.
Lead OrganizationRevolution Medicines
